Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.


NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc
Bullboard Posts
User Avatar Image
(65)
•••
Comment by StockscoutXon Nov 14, 2018 9:14pm
75 Views
Post# 28977086

RE:RE:RE:RE:RE:RE:RE:RE:DMA REVERSE SPLIT

RE:RE:RE:RE:RE:RE:RE:RE:DMA REVERSE SPLIT
This is the result from when the market has been spooked when the SP was manipulatied to trigger the selling from the march 20, 2018 private placement. Look at the chart. The proof is staring right before your eyes. Only a blind person will not see it. Ever since the trigger conditions the SP took a nose dive and never stopped. Moreover, everytime the SP tended to rally back up a wall was thrown up to block it. It's called the MM manipulating the SP to achieve a goal for another PP, a reverse split and get on the NASDAQ but at the cost of current shareholders.

The MM could drive the SP back up if they want to stop the bleeding like when they drove it up to trigger the sell..

All in my opinion.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities